NetwoRx Bio · raw details

Revolutionizing immunotherapy trials with AI-driven drug–indication–biomarker insights. · Tel Aviv-Yafo · Founded 2024

active Pre-Funding ← back to profile

Highlights

1 patentProfile claimed by owner

About

Revolutionizing immunotherapy trials with AI-driven drug–indication–biomarker insights.

NetwoRx Bio is unlocking the next generation of immunotherapy. We harness cutting-edge computational biology to decode the complex communication networks between immune, tumor, and stromal cells within the tumor microenvironment—revealing how these interactions drive treatment response and resistance.

Powered by proprietary data from our clinical trials and advanced AI-driven analytics, we generate the NetwoRx Score: a patient-specific metric that identifies the most actionable molecular interactions. This score predicts response to immune checkpoint inhibitors (ICIs), monoclonal antibodies, and small molecule immune modulators—transforming complexity into precision.

Our Value Proposition:

1. Optimal Clinical Trial Design Matching the right immunotherapeutic drugs or combinations to the right indication and patient population—enhancing trial success and development efficiency.

2. Precision Medicine Delivering personalized immunotherapy by identifying which patients are most likely to benefit from specific treatments.

NetwoRx Bio turns the hidden communication networks of the tumor microenvironment into a roadmap for smarter, faster, and more effective immunotherapy.

Identity

NameNetwoRx Bio
Slugnetworx-bio
Former namesPyxis Dx
Type / kindstartup
Source _idpFo3gkRReTVQLLRgnatRCJ9z0aeJOdaLg2zaJHUctu7QBbUDZCwqex

Status

Statusactive
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityTel Aviv-Yafo
HQ addressTel Aviv-Yafo, Israel

Web & social

Websitehttps://networx.bio/
LinkedInhttps://www.linkedin.com/company/107054316/

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life Sciences
Technologies
BiologicalsArtificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
treatmentsimmunologyimmunotherapycancercancer-therapyoncology

Funding

Total raised
Current stagePre-Funding

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}